

From: Chief Officer <chiefofficer@leics-lpc.co.uk>

Sent: 16 June 2026 08:31

To: Chief Officer <chiefofficer@leics-lpc.co.uk>

Cc: ServiceDevelopmentLead <ServiceDevelopmentLead@leics-lpc.co.uk>

Subject: Early Information on upcoming LLR ICB Medicines Formulary changes

FAO: ALL LLR Pharmacy Teams

We have been asked by the Leicester, Leicestershire and Rutland (LLR) Integrated Care Board Medicines Optimisation Team to share advance notice of forthcoming formulary alignment changes relating to denosumab prescribing across LLR. The ICB anticipates that the following changes will be implemented across GP practices in the coming months as part of ongoing formulary alignment work:

Proposed changes

Where clinically appropriate:

- **Jubereq® (Denosumab) 120mg/1.7ml solution for injection (vial)** will become the preferred first-line option in place of Xgeva®.
- **Ponlimisi® (Denosumab) 60mg solution for injection (pre-filled syringe)** will become the preferred first-line option in place of Prolia®.
- **Xgeva® and Prolia® will no longer be considered first-line formulary choices.**

The ICB has shared this information in advance to support community pharmacy contractors with forward planning, particularly in relation to stock management and ensuring continuity of care for patients who may be affected by these changes. Contractors may wish to be aware of the anticipated increase in prescribing of Jubereq® and Ponlimisi® once the formulary changes are implemented and consider any implications for stock availability and procurement processes. Thank you for your continued support in helping to ensure a smooth transition for patients across LLR.

Kind Regards
Rajshri Owen MRPharmS
Chief Officer